AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Apogee Therapeutics Inc. (APGE)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

33.96

0.04 (0.12%)

At close: Feb 20, 2025, 3:59 PM

33.95

-0.03%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	32.5
Market Cap	1.99B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.43
PE Ratio (ttm)	-13.98
Forward PE	n/a
Analyst	Buy

Ask	37
Volume	611,087
Avg. Volume (20D)	535,306
Open	33.95
Previous Close	33.92
Day's Range	32.46 - 34.54
52-Week Range	32.46 - 72.29
Beta	undefined

About APGE

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs inclu...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 14, 2023

Employees 91

Stock Exchange NASDAQ

Ticker Symbol APGE

Website https://www.apogeetherapeutics.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for APGE stock is "Buy." The 12-month stock price forecast is $89, which is an increase of 162.07% from the latest price.

Buy 83.33%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 months ago

-5.14%

Apogee Therapeutics shares are trading lower. The ... Unlock content with Pro Subscription

6 months ago

+10.59%

Apogree Therapeutics shares are trading higher after the company announced its initiated dosing of its clinical trail for APG990.

News

3 months ago · seekingalpha.com

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing and potential applications in asthma, COPD, and psoriasis. APGE's investigational pipeline includes AP...